Merck KGaA (XTRA:MRK) raised its full year 2026 guidance after third quarter results, lifting expected net sales to €21.5b to €21.9b and nudging EPS pre guidance up to €8.30 to €8.70.
Those guidance upgrades have landed in a market that had already been warming back up to Merck KGaA, with the 90 day share price return of 9.68% and year to date share price gain of 23.33% feeding into a 1 year total shareholder return of 29.82%, even though the 5 year total shareholder return is down 26.89%. This points to momentum rebuilding after a weak longer stretch.
Spot fresh momentum stories like Merck KGaA by scanning our curated list of 197 high quality undervalued stocks that pair rebuilding sentiment with solid fundamentals.Merck KGaA now has upgraded guidance and a sharp rebound in recent returns, yet the share price is still flagged at a sizeable intrinsic discount. Does the current setup still tilt the risk reward balance toward new buyers?
Merck KGaA closed at €149.60, just below the analyst consensus Narrative fair value of €154.21. This is built using a 5.41% discount rate and detailed revenue and earnings forecasts in the analyst consensus Narrative on Simply Wall St.
The main factor that has to go right is that Merck KGaA successfully integrates deals such as Bio-Techne and SpringWorks while keeping EBITDA pre margins in Life Science and Healthcare around current guidance levels.
The current valuation implies the market is discounting Merck KGaA’s raised 2026 guidance and the narrative that the company is undervalued and positive on its long-term cash generation from AI semiconductors, workflow solutions, and rare disease therapies.
See why 61 investors see Merck KGaA as 3% undervalued.
Result: Fair Value of €154.21 (UNDERVALUED)
Still, the Merck KGaA story can break if the integration of Bio-Techne drags on margins, or if Mavenclad erosion bites harder than new rare disease launches can offset.
Find out about the key risks to this Merck KGaA narrative.
Mixed signals on Merck KGaA so far, and you can see why opinion splits. Act while the data is fresh, and weigh both sides for yourself by checking the 3 key rewards and 2 important warning signs.
Do not stop with Merck KGaA. Broaden your watchlist now and give yourself more options before the next round of market moves leaves you reacting late.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com